The company
Evommune, Inc.
EVMN · NYSE
EVMN stood above a rising 150-day average in 0 of the last 14 weekly readings. It is 69.7% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 14
- Industry in uptrend
- 15% -17 in 4 wk
- Insider buys, 12 months
- $70.3M
- Insider sales, 12 months
- $4.6M
- Officials’ trades on record
- 0
- Institutions holding
- 105 (+23)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 0 of 14 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Kyle CarverChief Financial Officer | bought | 1,000at $13.26 | 8 Jul 2026filed 10 Jul 2026 |
| Arthur S. KirschDirector | bought | 10,000at $13.30 | 7 Jul 2026filed 8 Jul 2026 |
| Luis C. PenaPresident & CEO | sold | 7,438at $22.71 | 22 Jun 2026filed 24 Jun 2026 |
| Janice Suzann DrewChief of Dev. Operations | sold | 20,000at $22.63 | 22 Jun 2026filed 24 Jun 2026 |
| Jeegar Pravinkumar PatelChief Scientific Officer | sold | 1,488at $22.50 | 22 Jun 2026filed 24 Jun 2026 |
| David E. CohenDirector | sold | 5,456at $20.21 | 2 Jun 2026filed 3 Jun 2026 |
| David E. CohenDirector | sold | 600at $21.38 | 2 Jun 2026filed 3 Jun 2026 |
| Luis C. PenaPresident & CEO | sold | 16,787at $22.74 | 1 Jun 2026filed 3 Jun 2026 |
| Jeegar Pravinkumar PatelChief Scientific Officer | sold | 16,687at $22.74 | 1 Jun 2026filed 3 Jun 2026 |
| Gregory S. MossChief Business & Legal Officer | sold | 14,223at $22.83 | 28 May 2026filed 1 Jun 2026 |
| Kyle CarverChief Financial Officer | sold | 18,175at $22.84 | 28 May 2026filed 1 Jun 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| EQT Fund Management S.a r.l.added · filed 13 Aug 2026 | 5,288,313$70.3M | +358,680+7.3% |
| RA CAPITAL MANAGEMENT, L.P.unchanged · filed 14 Aug 2026 | 3,494,638$46.4M | 00.0% |
| Pivotal bioVenture Partners Investment Advisor LLCunchanged · filed 13 Aug 2026 | 1,926,943$25.6M | 00.0% |
| JPMORGAN CHASE & COnew · filed 12 Aug 2026 | 1,553,132$23.4M | +1,553,132 |
| RTW INVESTMENTS, LPunchanged · filed 14 Aug 2026 | 1,502,235$20.0M | 00.0% |
| Nan Fung Group Holdings Ltdunchanged · filed 13 Aug 2026 | 1,441,032$19.2M | 00.0% |
| Point72 Asset Management, L.P.added · filed 14 Aug 2026 | 1,435,049$19.1M | +1,398,472+3823.4% |
| ANDERA PARTNERSreduced · filed 22 Jul 2026 | 1,391,990$18.5M | -505,372−26.6% |
| EVENTIDE ASSET MANAGEMENT, LLCunchanged · filed 14 Aug 2026 | 1,209,129$16.1M | 00.0% |
| Vestal Point Capital, LPnew · filed 14 Aug 2026 | 1,000,000$13.3M | +1,000,000 |
News
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.